Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder".
Saved in:
| Title: | Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder". |
|---|---|
| Authors: | Price, Maxwell Z. (AUTHOR), Price, Richard L. (AUTHOR) |
| Source: | CNS Drugs. Oct2023, Vol. 37 Issue 10, p939-940. 2p. |
| Subjects: | Attention-deficit hyperactivity disorder, Atomoxetine, Benzodiazepines, Caffeine |
| Abstract: | We recognize that a paradigm shift of this magnitude takes time, as psychostimulants have been the mainstay of pharmacologic ADHD treatment for generations, but we are grateful to the editor for giving us this forum to share the experiences of our patients and their families from which we can learn. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder" Following the 5-day washout period of atomoxetine, post-treatment scores were compared with baseline pretreatment scores to confirm that baseline scores were re-established prior to initiating viloxazine extended release (VER). [Extracted from the article] |
| Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | We recognize that a paradigm shift of this magnitude takes time, as psychostimulants have been the mainstay of pharmacologic ADHD treatment for generations, but we are grateful to the editor for giving us this forum to share the experiences of our patients and their families from which we can learn. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder" Following the 5-day washout period of atomoxetine, post-treatment scores were compared with baseline pretreatment scores to confirm that baseline scores were re-established prior to initiating viloxazine extended release (VER). [Extracted from the article] |
|---|---|
| ISSN: | 11727047 |
| DOI: | 10.1007/s40263-023-01035-2 |
